Eli Lilly’s diabetes medication Mounjaro demonstrated cardiovascular outcomes comparable to existing treatments in a large-scale trial. The drug reduced the risk of heart-related events by 8% compared to the somewhat older treatment Trulicity and showed a 16% reduction in all-cause mortality, although this latter result was not statistically conclusive. These findings support Lilly’s efforts toward expanding Mounjaro’s label and highlight its dual benefit in metabolic and cardiovascular disease management.